Fate Therapeutics Inc (NASDAQ:FATE) — Market Cap & Net Worth
Market Cap & Net Worth: Fate Therapeutics Inc (FATE)
Fate Therapeutics Inc (NASDAQ:FATE) has a market capitalization of $131.50 Million ($131.50 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18234 globally and #4270 in its home market, demonstrating a -5.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fate Therapeutics Inc's stock price $2.35 by its total outstanding shares 115352289 (115.35 Million). Also see how large is Fate Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Fate Therapeutics Inc Market Cap History: 2015 to 2026
Fate Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $388.74 Million to $271.08 Million (-5.49% CAGR). Also see Fate Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Fate Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #509 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1778 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.01% | #238 of 263 |
Weight: Fate Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Fate Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fate Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Fate Therapeutics Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
13.96x
Fate Therapeutics Inc's market cap is 13.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $388.74 Million | $2.43 Million | -$29.99 Million | 159.91x | N/A |
| 2016 | $289.53 Million | $4.40 Million | -$33.46 Million | 65.77x | N/A |
| 2017 | $704.80 Million | $4.11 Million | -$42.95 Million | 171.65x | N/A |
| 2018 | $1.48 Billion | $4.74 Million | -$66.60 Million | 312.23x | N/A |
| 2019 | $2.26 Billion | $10.68 Million | -$98.15 Million | 211.37x | N/A |
| 2020 | $10.49 Billion | $31.43 Million | -$173.39 Million | 333.68x | N/A |
| 2021 | $6.75 Billion | $55.85 Million | -$212.15 Million | 120.85x | N/A |
| 2022 | $1.16 Billion | $96.30 Million | -$255.06 Million | 12.09x | N/A |
| 2023 | $431.42 Million | $63.53 Million | -$160.93 Million | 6.79x | N/A |
| 2024 | $190.33 Million | $13.63 Million | -$186.26 Million | 13.96x | N/A |
Competitor Companies of FATE by Market Capitalization
Companies near Fate Therapeutics Inc in the global market cap rankings as of September 17, 2026. Review FATE tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Fate Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Fate Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Fate Therapeutics Inc's market cap moved from $388.74 Million to $ 271.08 Million, with a yearly change of -5.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $271.08 Million | +139.16% |
| 2025 | $113.35 Million | -40.45% |
| 2024 | $190.33 Million | -55.88% |
| 2023 | $431.42 Million | -62.93% |
| 2022 | $1.16 Billion | -82.76% |
| 2021 | $6.75 Billion | -35.65% |
| 2020 | $10.49 Billion | +364.64% |
| 2019 | $2.26 Billion | +52.53% |
| 2018 | $1.48 Billion | +109.98% |
| 2017 | $704.80 Million | +143.43% |
| 2016 | $289.53 Million | -25.52% |
| 2015 | $388.74 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Fate Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $131.50 Million USD |
| MoneyControl | $131.50 Million USD |
| MarketWatch | $131.50 Million USD |
| marketcap.company | $131.50 Million USD |
| Reuters | $131.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more